AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline
by Zacks Equity Research
Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $65.86, marking a -0.6% move from the previous day.
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
by Zacks Equity Research
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
by Kinjel Shah
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study
by Zacks Equity Research
Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
by Zacks Equity Research
GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
by Zacks Equity Research
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Astrazeneca (AZN) closed at $65.86 in the latest trading session, marking a +0.02% move from the prior day.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
by Zacks Equity Research
AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
by Kinjel Shah
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
by Zacks Equity Research
AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Astrazeneca (AZN) reachead $67.58 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
by Zacks Equity Research
Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $66.19, moving +1.41% from the previous trading session.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Astrazeneca (AZN) stood at $64.60, denoting a +0.69% change from the preceding trading day.
The Zacks Analyst Blog Highlights Costco Wholesale, The Walt Disney, AstraZeneca, O'Reilly Automotive and Restaurant Brands International
by Zacks Equity Research
Costco Wholesale, The Walt Disney, AstraZeneca, O'Reilly Automotive and Restaurant Brands International are part of the Zacks top Analyst Blog.
Top Stock Reports for Costco, Walt Disney & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), The Walt Disney Company (DIS) and AstraZeneca PLC (AZN).
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
by Kinjel Shah
The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively
Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.